Mark J. Ratain to Prostate-Specific Antigen
This is a "connection" page, showing publications Mark J. Ratain has written about Prostate-Specific Antigen.
Connection Strength
0.520
-
Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing? J Clin Oncol. 2005 Nov 01; 23(31):8124-5; author reply 8125-6.
Score: 0.229
-
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol. 2018 05 10; 36(14):1389-1395.
Score: 0.135
-
Metabolism of megestrol acetate in vitro and the role of oxidative metabolites. Xenobiotica. 2018 Oct; 48(10):973-983.
Score: 0.132
-
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. Cancer. 2004 Jan 01; 100(1):65-71.
Score: 0.013
-
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. J Clin Oncol. 2002 Aug 15; 20(16):3369-75.
Score: 0.011